Abstract 1044P
Background
For product development, GMP production, quality control for product release and immune monitoring of patient samples, three methods are typically used to identify rTCR expression in TCR-T populations: (1) detection of an extra tag that is co-expressed with the rTCR; (2) binding of antibodies specific for TCR Vß-chains, or (3) rTCR binding of peptide-HLA multimers. The latter two approaches must be tailored for each rTCR and high-quality reagents may not be readily available.
Methods
Using bioinformatics and 3D modeling of TCRs, novel synthetic epitopes were designed and inserted at different positions in multiple rTCR sequences. Internally tagged rTCRs were assessed for surface expression, functionality and target specificity, as well as for binding of an antibody (TraCR) detecting the synthetic epitopes of different length.
Results
Identifying a unique, synthetic epitope (UniTope) and optimal insertion sites localized in the rTCR constant regions permitted highly specific detection by the TraCR antibody. The UniTope & TraCR combination unambiguously distinguishes rTCRs expressed in recipient T cells from all endogenous TCRs found in PBL. The integrated UniTope tag exclusively binds TraCR antibody, and not alter functionality, established safety profiles or expression levels of any of the assessed rTCRs.
Conclusions
UniTope & TraCR is a universal detection system for rTCRs easy to adapt for multi-parameter flow cytometry. Seamless integration of UniTope in any rTCR structure bypasses need for co-expression of a separate gene sequence to universally tag rTCR-expressing T cells. Providing a standardized detection system, UniTope & TraCR simplifies supply and validation of quality control assays for TCR-T therapies covering all rTCRs, providing precise information for drug product dosing. It allows easy visualization, isolation and enrichment of TCR-T cells for direct study. GMP-grade TraCR can be applied for drug product enrichment and potentially also to trace TCR-T cell localization and persistence in vivo, supporting immune monitoring in patients. The UniTope & TraCR system is a high precision technology that facilitates optimized development of TCR-T therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1046P - Genetic alteration profile and T Cell receptor repertoire in severe immune-related adverse events during checkpoint immunotherapy
Presenter: Yi Hu
Session: Poster session 03
Resources:
Abstract
1047P - Tocilizumab is an effective secondary prophylaxis during immune checkpoint inhibitor rechallenge following arthritis
Presenter: Michel Obeid
Session: Poster session 03
1048P - Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: Evidence from a Belgian real-world multicenter study
Presenter: Danielle Delombaerde
Session: Poster session 03
1049P - Cytokine release syndrome in patients treated with bispecific T cell engagers and bispecific monoclonal antibodies at The Christie: A retrospective study
Presenter: Mariam Shalaby
Session: Poster session 03
1050P - Independent of calendric age, T cells are phenotypically less senescent in successfully ICI-treated cancer patients that developed irAE
Presenter: Sarah Roffeis
Session: Poster session 03
1051P - Impact of TLS status on outcomes in patients with high TMB or MSI-high status treated with immune checkpoint inhibitors
Presenter: Antoine Italiano
Session: Poster session 03
Resources:
Abstract
1052P - Pan-cancer, multi-omic analysis of 'hot' and 'cold' tumors reveals immunotherapy relevant signatures
Presenter: Elisabetta Nale
Session: Poster session 03
1053P - The prognostic value of systemic inflammatory markers among patients receiving immune checkpoint inhibitors (ICIs): A population-based study
Presenter: Abdulrahman Alghabban
Session: Poster session 03
1054P - CRUCIAL: Analysis of the incidence of second primary cancers in the Spanish thoracic tumor registry according to treatment
Presenter: Mariano Provencio Pulla
Session: Poster session 03
1055P - Analysis of correlation between quality of life (QoL) results and survival outcomes in phase III clinical trials testing immunotherapy in metastatic cancers
Presenter: Annarita Avanzo
Session: Poster session 03